Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to study entry
Karnofsky Performance Status of \>/= 70 at screening
Confirmed measurable disease per RANO
Adequate hematologic and organ function
Patients enrolled in Stage 1:
Histologically documented recurrent or progressive high-grade gliomas (WHO Grade III-IV)
Prior treatment with at least one regimen for gliomas (radiotherapy with or without chemotherapy for Grade III gliomas and radiotherapy with chemotherapy for Grade IV gliomas) and/or not considered to be a candidate for regimens known to provide clinical benefit
Patients enrolled in Stage 2:
Histologically documented recurrent or progressive glioblastoma (WHO Grade IV gliomas)
Prior treatment with one or two regimens for glioblastoma (with the initial regimen consisting of radiotherapy with chemotherapy)
You may not be if
Treatment with anti-tumor therapy (approved or experimental) within 4 weeks prior to initiation of study drug
Requirement for anticoagulants such as warfarin or any other warfarin-derivative anticoagulants; low-molecular-weight heparin is permitted
Any contraindication to MRI examination
Evidence of Grade \>/= 1 intracranial hemorrhage
Active congestive heart failure or ventricular arrhythmia requiring medication
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse or cirrhosis
Unresolved toxicity from prior therapy with the exception of lymphopenia (for patients with prior temozolomide) and alopecia
